- Home
- CFBK vs CCCC Comparison
CFBK vs CCCC Comparison
Compare CFBK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- CCCC
- Stock Information
- Founded
- CFBK 1892
- CCCC 2015
- Country
- CFBK United States
- CCCC United States
- Employees
- CFBK N/A
- CCCC N/A
- Industry
- CFBK Major Banks
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- CFBK Finance
- CCCC Health Care
- Exchange
- CFBK Nasdaq
- CCCC Nasdaq
- Market Cap
- CFBK 159.5M
- CCCC 175.1M
- IPO Year
- CFBK 1998
- CCCC 2020
- Fundamental
- Price
- CFBK $25.50
- CCCC $2.71
- Analyst Decision
- CFBK Buy
- CCCC Buy
- Analyst Count
- CFBK 1
- CCCC 3
- Target Price
- CFBK $29.00
- CCCC $8.00
- AVG Volume (30 Days)
- CFBK 33.1K
- CCCC 1.2M
- Earning Date
- CFBK 10-29-2025
- CCCC 10-30-2025
- Dividend Yield
- CFBK 1.29%
- CCCC N/A
- EPS Growth
- CFBK 36.66
- CCCC N/A
- EPS
- CFBK 2.77
- CCCC N/A
- Revenue
- CFBK $52,793,000.00
- CCCC $34,240,000.00
- Revenue This Year
- CFBK $39.98
- CCCC N/A
- Revenue Next Year
- CFBK $10.47
- CCCC N/A
- P/E Ratio
- CFBK $8.93
- CCCC N/A
- Revenue Growth
- CFBK 20.91
- CCCC 16.55
- 52 Week Low
- CFBK $19.23
- CCCC $1.09
- 52 Week High
- CFBK $31.17
- CCCC $7.22
- Technical
- Relative Strength Index (RSI)
- CFBK 70.44
- CCCC 60.74
- Support Level
- CFBK $24.28
- CCCC $2.33
- Resistance Level
- CFBK $25.08
- CCCC $2.85
- Average True Range (ATR)
- CFBK 0.40
- CCCC 0.19
- MACD
- CFBK 0.03
- CCCC -0.01
- Stochastic Oscillator
- CFBK 72.67
- CCCC 71.03
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.